Atopix Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Atopix Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011911
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Atopix Therapeutics Ltd (Atopix) is a clinical stage biotechnology company that develops novel treatments for Th2-mediated eosinophilic asthma. The company’s product portfolio includes CRTH2 used in the treatment of atopic dermatitis. It also offers ATX2417 and OC459 used in treatment of asthma and severe allergic conditions such as eye diseases. The company’s products are used in the therapeutic areas of atopic dermatitis, asthma and allergic rhinitis. It has a pipeline of small molecule drugs, the most advanced of which OC459 is being assessed in proof-of-concept clinical trials. Atopix is headquartered in Abingdon, the UK.

Atopix Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 10
Venture Financing 12
Atopix Therapeutics Raises Additional Funds through Venture Financing 12
Atopix Therapeutics Raises Funds through Extended Series A Financing 13
Atopix Raises USD5.7 Million in Series A Financing Round 14
Licensing Agreements 15
Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 15
Acquisition 16
Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 16
Atopix Therapeutics Ltd – Key Competitors 17
Atopix Therapeutics Ltd – Key Employees 18
Atopix Therapeutics Ltd – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Atopix Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Atopix Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 10
Atopix Therapeutics Raises Additional Funds through Venture Financing 12
Atopix Therapeutics Raises Funds through Extended Series A Financing 13
Atopix Raises USD5.7 Million in Series A Financing Round 14
Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 15
Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 16
Atopix Therapeutics Ltd, Key Competitors 17
Atopix Therapeutics Ltd, Key Employees 18

★海外企業調査レポート[Atopix Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mangalore Refinery and Petrochemicals Ltd (MRPL):企業の財務・戦略的SWOT分析
    Mangalore Refinery and Petrochemicals Ltd (MRPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Vericel Corp (VCEL):製薬・医療:M&Aディール及び事業提携情報
    Summary Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts fo …
  • Pfizer Inc (PFE):医療機器:M&Aディール及び事業提携情報
    Summary Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, …
  • Alexion Pharmaceuticals Inc (ALXN)-製薬・医療分野:企業M&A・提携分析
    Summary Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic d …
  • Sterling Holiday Resorts (India) Limited:企業の戦略・SWOT・財務情報
    Sterling Holiday Resorts (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Sterling Holiday Resorts (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Groupe Bruxelles Lambert SA:企業の戦略・SWOT・財務情報
    Groupe Bruxelles Lambert SA - Strategy, SWOT and Corporate Finance Report Summary Groupe Bruxelles Lambert SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Origin Energy Ltd (ORG):企業の財務・戦略的SWOT分析
    Origin Energy Ltd (ORG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • InspireMD Inc (NSPR):医療機器:M&Aディール及び事業提携情報
    Summary InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for us …
  • General Dynamics Land Systems Inc:企業の戦略・SWOT・財務情報
    General Dynamics Land Systems Inc - Strategy, SWOT and Corporate Finance Report Summary General Dynamics Land Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Lendlease Corporation Limited (LLC):企業の財務・戦略的SWOT分析
    Lendlease Corporation Limited (LLC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Harbin Gloria Pharmaceuticals Co Ltd (002437):製薬・医療:M&Aディール及び事業提携情報
    Summary Harbin Gloria Pharmaceuticals Co Ltd (Harbin Gloria) is a pharmaceutical company that produces and markets nutritional drugs. The company’s products include pharmaceutical drugs for treating nutrition disorders, cancer, cardiovascular diseases, antitumor medication, respiratory medication, a …
  • Regen BioPharma Inc (RGBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Regen BioPharma Inc (Regen BioPharma), a subsidiary of Bio-Matrix Scientific Group Inc, is an immunology and immunotherapy space provider. The company concentrates on the development of immunotherapies and cancer stem cell therapies. Its product pipeline includes HemaXellerate, dCellVax, Dif …
  • China Foods Limited:企業の戦略・SWOT・財務情報
    China Foods Limited - Strategy, SWOT and Corporate Finance Report Summary China Foods Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • ManpowerGroup Inc (MAN):企業の財務・戦略的SWOT分析
    ManpowerGroup Inc (MAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • LSIS Co Ltd (010120):企業の財務・戦略的SWOT分析
    LSIS Co Ltd (010120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SymBio Pharmaceuticals Ltd (4582):製薬・医療:M&Aディール及び事業提携情報
    Summary SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. The company develops SyB drugs, treakisym and rigosertib, among others. It offers business development services in areas of oncology, hematology and pain-management areas …
  • Japan Tobacco Inc.:企業の戦略・SWOT・財務情報
    Japan Tobacco Inc. - Strategy, SWOT and Corporate Finance Report Summary Japan Tobacco Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • China Grand Pharmaceutical and Healthcare Holdings Ltd (512)-医療機器分野:企業M&A・提携分析
    Summary China Grand Pharmaceutical and Healthcare Holdings Ltd (China Grand) is an investment holding company that develops, manufacture and distributes pharmaceutical preparations, medical devices and pharmaceutical intermediates, specialized raw materials, and healthcare products. The company’s pr …
  • RentPath LLC:企業の戦略的SWOT分析
    RentPath LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Rentschler Biotechnologie GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Rentschler Biotechnologie GmbH (Rentschler), a subsidiary of Dr. Rentschler Holding GmbH & Co KG is a contract development and manufacturing organization that develops and manufactures biopharmaceuticals. The organization offers bioprocess development, biomanufacturing, and consulting servic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆